Table 2

Clinical outcomes in COVID-19 patients treated with baricitinib

All cases<65 years old>65 years old
Population
Number of patents20214656
Female, %484752
Mean age (range), years58 (25–92)52 (25–64)75 (65–92)
Mean treatment duration (range), days6 (1–35)6 (1–11)7 (1–35)
Dexamethasone, %7.47.57.1
Disease (on admission)
Clinical severity, %
 Mild3.03.41.8
 Moderate95.095.294.6
 Severe2.01.43.6
 Critical01.00
Lung involvement, %
 CT 0000
 CT 18.07.519.0
 CT 271.268.578.5
 CT 320.824.012.5
 CT 4000
C reactive protein: clinically significant abnormality, %9592100
Outcomes
Death, n (%)9 (4.5)3 (2.1)6 (10.7)
Mean from hospitalisation till death (range), days12 (2–32)14 (2–32)12 (5–20)
ICU admission, n (%)19 (9.4)10 (6.9)9 (16.1)
Mean stay in ICU (range), days7 (1–30)9 (1–30)5 (1–13)
Mechanical ventilation, n (%)8 (4.0)4 (2.8)4 (7.1)
Mean duration of mechanical vent. (range), days7 (2–22)9 (3–22)6 (2–13)
Safety
Thromboses, n (%)1 (0.5)0 (0)1 (1.8)
Pulmonary embolism, n (%)1 (0.5)0 (0)1 (1.8)
Infectious complications, n (%)7 (3.5)4 (2.8)3 (5.4)
  • ICU, intensive care unit.